Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Cunningham

Showing results (451-460 of 465) with videos related to

Pageof 47
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The American Journal of Hospice & Palliative Care|January 8, 2019
Trauma Surgeon and Palliative Care Physician Attitudes Regarding Goals-of-Care Delineation for Injured Geriatric PatientsHolly B Cunningham, Shannon A Scielzo, Paul A Nakonezny, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Canadian Liver Journal|August 22, 2022
Striving toward hepatitis C elimination in the era of COVID-19Charlotte Lanièce Delaunay, Zoë R Greenwald, Nanor Minoyan, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2022
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antiviralsAnita Y M Howe, Chaturaka Rodrigo, Evan B Cunningham, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Environmental Science & Technology|February 10, 2022
In Situ Enhancement and Isotopic Labeling of Biogenic Coalbed MethaneElliott P Barnhart, Leslie F Ruppert, Randy Hiebert, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 47

Showing results (451-460 of 465) with videos related to

Sort By:
Pageof 47
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject DrugsEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The American Journal of Hospice & Palliative Care|January 8, 2019
Trauma Surgeon and Palliative Care Physician Attitudes Regarding Goals-of-Care Delineation for Injured Geriatric PatientsHolly B Cunningham, Shannon A Scielzo, Paul A Nakonezny, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Canadian Liver Journal|August 22, 2022
Striving toward hepatitis C elimination in the era of COVID-19Charlotte Lanièce Delaunay, Zoë R Greenwald, Nanor Minoyan, et al.
The International Journal on Drug Policy|January 6, 2026
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison: a systematic review and meta-analysisEvan B Cunningham, Alice Wheeler, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|April 18, 2022
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antiviralsAnita Y M Howe, Chaturaka Rodrigo, Evan B Cunningham, et al.
The International Journal on Drug Policy|June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C studyJoshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
Environmental Science & Technology|February 10, 2022
In Situ Enhancement and Isotopic Labeling of Biogenic Coalbed MethaneElliott P Barnhart, Leslie F Ruppert, Randy Hiebert, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Pageof 47